FILING ANALYSIS · TUESDAY, OCTOBER 27
Kiniksa Pharmaceuticals International, plc KNSA — 8-K: Results of Operations and Financial Condition
positive
Kiniksa Pharmaceuticals reported strong Q3 2026 financial results with ARCALYST net product revenue of $286.0 million, representing 58% year-over-year growth, and raised 2026 ARCALYST net product revenue guidance to $1.045-1.050 billion
The filing
8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →